The in-vitro activity of BMY 28142, a new o-methoxyimino aminothiazolyl cephalosporin, was determined by microdilution broth techniques. The agent demonstrated excellent activity against recent clinical Enterobacteriaceae isolates with a 90% minimum inhibitory concentration (MIC 90 ) of 0-25 mg/1 or less for all but one species tested. BMY 28142 inhibited all Pseudomonas aeruginosa strains tested (MIC 90 = 8-0 mg/1) as well as most other non-fermentative bacteria studied. Methicillin-susceptible Staphylococcus aureus were susceptible to BMY 28142 with MIC 90 = 4-0 mg/1, while methicillin-resistant strains were generally resistant (MIC range 8-> 32 mg/1).
Introduction
BMY 28142 is a new a-methoxyimino aminothiazolyl cephalosporin with a Af-methyl pyrrolidine substituent at the 3 position of the dihydrothiazolidine ring ( Figure 1 ). Based on its structural similarity to cefotaxime and related aminothiazolyl cephalosporins, BMY 28142 could be expected to exhibit substantial in-vitro activity against strains of Enterobacteriaceae and other Gram-negative bacilli (Neu, 1982) . In order to confirm this, the activity of BMY 28142 against fresh clinical isolates of aerobic Gram negative bacilli was determined by broth microdilution techniques and compared to that of other new /Mactam agents. Additionally, the activity against Staphylococcus aureus was measured to better delineate the antibacterial spectrum of BMY 28142. 
Methods
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Bacterial strains. Susceptibility testing was routinely performed on all Gram-negative bacillary isolates from current cultures received over a ten-week period in the Clinical Microbiology Laboratory at the Medical College of Georgia Hospitals and Clinics. Isolates were identified with commercial identification systems (API 20E, Analytab Products, Plainview, N.Y., or DMS Rapid NFT, DMS Laboratories, Inc., Flemington, N.J.). Repeat isolates were excluded from data analysis, yielding 339 Enterobacteriaceae and 96 non-Enterobacteriaceae. Additionally, susceptibility to BMY 28142 was determined for 28 consecutive, current methicillin-susceptible isolates and five recent methicillin-resistant stock strains ofStaph. aureus. Susceptibility testing. Minimum inhibitory concentrations (MICs) were determined by standard broth microdilution techniques (National Committee for Clinical Laboratory Standards, 1983) . Briefly, sequential two-fold dilutions were prepared in cationsupplemented Mueller-Hinton broth over the range 0016-32mg/1. Four-hour broth cultures of the organism were diluted to provided a final organism density of approximately 5 x 10 s cfu/ml in a volume of 01 ml. The purity of each inoculum was confirmed by subculture. The MIC was read as the lowest antibiotic concentration showing no visible growth after 18 h of aerobic incubation at 35°C. Fifty per cent MICs (MIC 50 ), 90% MICs (MIC 90 ) and geometric mean MICs (MIC GM ) were calculated after excluding repeat isolates. The MIC GM was computed using the lowest concentration shown to be inhibitory in the tested agent's dilution scheme even if this was the lowest concentration tested. Minimum bactericidal concentrations were determined for Staph. aureus isolates by quantitatively subculturing the entire contents of appropriate wells to individual 10 cm agar plates to determine 99-9% killing. Daily quality control performed with Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 yielded MICs of :g0016 mg/1 and of 1-2 mg/1, respectively, on 95% of the determinations.
Results
The in-vitro activity of BMY 28142 against 339 Enterobacteriaceae isolates is compared with that of other /Mactam agents in Table I . Excellent inhibitory activity was found with MIC 50^0 031 mg/1 and MIC 9O g0-25mg/1 against the tabulated species. Other Enterobacteriaceae tested (number of isolates in parentheses) included Cedecea spp. (1) Providencia rettgeri (2), Prov. stuartii (4), Salmonella enteriditis (4), and Serratia spp.
(1). All had BMY 28142 MICs = 0-25 mg/1 except for the single Proteus species isolate for which the MIC was 16 mg/1. None of the Enterobacteriaceae isolates tested were resistant (MIC> 16 mg/1) to BMY 28142.
Compared to the other antimicrobial agents, BMY 28142 was the most active. While cefotaxime demonstrated an activity similar to that of BMY 28142 against several species, it was much less active against Enterobacter and Serratia spp. isolates. Six cefotaxime-resistant isolates (all Enterobacter spp.) were susceptible to BMY 28142 (MIC range 0125-20mg/1). The other/Mactam antibiotics tested were somewhat less active. However, as with cefotaxime, actual resistance was uncommon, ranging from two to nine isolates.
Against Acinetobacter calcoaceticus subsp. anitratus isolates BMY 28142 had an activity comparable to that of ceftazidime but superior to that of the other cephalosporins; imipenem was the most active agent against this organism. All seventy strains of Ps. aeruginosa tested were susceptible to BMY 28142, activity similar to that seen with cefoperazone and ceftazidime but probably less than that of imipenem. Similar activity comparisons were found in the 37 gentamicin-resistant strains of Ps. aeruginosa and in the 19 other Pseudomonas spp. tested (Table II) . Only one of seven isolates of Ps. maltophilia was resistant (MIC = 32 mg/1).
BMY 28142 showed good activity against 28 methicillin-susceptible isolates of Staph. aureus with MIC GM = 3-3mg/1 and MIC 90 = 4-0mg/1 (range 1 0-40mg/1). Minimum bactericidal concentrations were the same as the MIC for 19 strains and one dilution higher for eight others; one isolate demonstrated tolerance to the agent (MIC = 1 0 mg/1; MBC> 16 mg/1). Five methicillin-resistant strains demonstrated greater resistance with MIC GM = 211 mg/1, MIC 50 = 16 + mg/1 and MIC 90 > 32 mg/1 (range 80-> 32 mg/1).
Discussion
BMY 28142 has been shown to have excellent in-vitro activity against the Enterobacteriaceae (Khan et al., 1984) . However, its superior activity compared to other new /Mactam agents was not appreciated as dilutions were not extended beyond 0-25 mg/1. The present work indicates that BMY 28142 is more active than the structurally related cefotaxime and the other antibiotics tested, particularly against species of Enterobacter and Serratia. Furthermore, Enterobacteriaceae isolates resistant to one or more of these agents remain susceptible to BMY 28142.
The good activity of BMY 28142 against non-fermentative bacteria other than Ps. maltophilia and Ps. cepacia has been found by others (van Landuyt, Boelaert & Lambert, 1984; Conrad et al., 1984) . Similarly, acceptable activity against methicillin-susceptible Staph. aureus strains has been reported (van Landuyt et al., 1984) . This wide spectrum of activity coupled with the extreme susceptibility of commonly isolated Enterobacteriaceae indicate that BMY 28142 is a promising new antimicrobial agent. Animal and clinical trials of its in-vivo potency are certainly warranted.
